Literature DB >> 29763617

A-to-I RNA Editing: An Overlooked Source of Cancer Mutations.

Shay Ben-Aroya1, Erez Y Levanon2.   

Abstract

RNA editing is a source of transcriptomic diversity, mainly in non-coding regions, and is found to be altered in cancer. In this issue of Cancer Cell, Peng et al. show that RNA editing events are manifested at the proteomic levels and are a source of cancer protein heterogeneity.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh：

Year:  2018        PMID： 29763617     DOI： 10.1016/j.ccell.2018.04.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

1.  Identification of neoantigens derived from alternative splicing and RNA modification.

Authors:  Jiyeon Park; Yeun-Jun Chung
Journal:  Genomics Inform       Date:  2019-08-22

2.  Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer.

Authors:  Chi Zhou; Zhiting Wei; Liye Zhang; Zhaoyi Yang; Qi Liu
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

Review 3.  A-to-I RNA Editing in Cancer: From Evaluating the Editing Level to Exploring the Editing Effects.

Authors:  Heming Wang; Sinuo Chen; Jiayi Wei; Guangqi Song; Yicheng Zhao
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

Review 4.  Functions and consequences of AID/APOBEC-mediated DNA and RNA deamination.

Authors:  Riccardo Pecori; Salvatore Di Giorgio; J Paulo Lorenzo; F Nina Papavasiliou
Journal:  Nat Rev Genet       Date:  2022-03-07       Impact factor: 59.581

5.  Conservation of A-to-I RNA editing in bowhead whale and pig.

Authors:  Knud Larsen; Mads Peter Heide-Jørgensen
Journal:  PLoS One       Date:  2021-12-09       Impact factor: 3.240

6.  Development and Validation of a Four Adenosine-to-Inosine RNA Editing Site-Relevant Prognostic Signature for Assessing Survival in Breast Cancer Patients.

Authors:  Jian Wan; Shizhen Chen; Anqin Zhang; Yiting Liu; Yangyang Zhang; Qinghua Li; Ziqi Yu; Yuwei Wan; Lei Yang; Qi Wang
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

Review 7.  Current challenges and best practices for cell-free long RNA biomarker discovery.

Authors:  Lluc Cabús; Julien Lagarde; Joao Curado; Esther Lizano; Jennifer Pérez-Boza
Journal:  Biomark Res       Date:  2022-08-18

8.  A-to-I nonsynonymous RNA editing was significantly enriched in the ubiquitination site and correlated with clinical features and immune response.

Authors:  Haixia Li; Juchuanli Tu; Jianjun Wang
Journal:  Sci Rep       Date:  2022-09-05       Impact factor: 4.996

Review 9.  RNA editing in the forefront of epitranscriptomics and human health.

Authors:  Theodoulakis Christofi; Apostolos Zaravinos
Journal:  J Transl Med       Date:  2019-09-23       Impact factor: 5.531
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.